Acquisition of TGF-β1 resistance: An important progression factor in human renal cell carcinoma

Laboratory Investigation

Volumn 76, Issue 5, 1997, Pages 739-749

  Ramp, Uwe ^a   Jaquet, Kai ^a   Reinecke, Petra ^a   Nitsch, Thorsten ^a   Gabbert, Helmut Erich ^a   Gerharz, Claus Dieter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CANCER GROWTH; CELL PROLIFERATION; DNA SEQUENCE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0030918629     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. 1 independent of effects on gene transcription. Cancer Res 55:3928-3932.
2. Barnard JA, Lyons RM, and Moses HL (1990). The cell biology of transforming growth factor beta. Biochim Biophys Acta 1032:79-87.
3. Bennington JL, Strathearn M, Spencer EM, and Williams RD (1990). Implications of insulin-like growth factors in renal cell carcinoma. Eur Urol 18:13-14.
4. Bruijn JA, Roos A, De Geus B, and De Heer E (1994). Transforming growth factor-β and the glomerular extracellular matrix in renal pathology. J Lab Clin Med 123:34-47.
5. Chirgwin JM, Przybyla AE, MacDonald RJ, and Rutter WJ (1979). Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18:5294-5299.
6. Creely JJ, Dimari SJ, Howe AM, and Haralson MA (1992). Effects of transforming growth factor-beta on collagen synthesis by normal rat kidney epithelial cells. Am J Pathol 140:45-55.
7. Damjanov I (1991). Growth factor receptors. In: Berry CL and Grundmann E, editors. Current topics in pathology, vol 83. Berlin: Springer Verlag, 159-186.
8. Dijke P, Yamashita H, Ichijo H, Franzen P, Laiho M, Miyazono K, and Heldin C-H (1994). Characterization of type I receptors for transforming growth factor-beta and activin. Science 264:101-104.
9. Ebner R, Chen R-H, Shum L, Lawler S, Zioncheck TF, Lee A, Lopez AR, and Derynck R (1993). Cloning of a type I TGF-beta receptor and its effect on TGF-beta binding to the type II receptor. Science 260:1344-1348.
10. Emoto N, Isozaki O, Ohmura E, Ito F, Tsushima T, Shizume K, Demura H, and Toma H (1994). Basic fibroblast growth factor (FGF-2) in renal cell carcinoma, which is indistinguishable from that in normal kidney, is involved in renal cell carcinoma growth. J Urol 152:1626-1631.
11. Gerharz CD, Hildebrandt B, Moll R, Ramp U, Sarbia M, Störkel S, Koldovsky P, and Gabbert HE (1996). Chromophilic renal cell carcinoma: Cytomorphological and cytogenetic characterization of four permanent cell lines. Br J Cancer 74:1605-1614.
12. Gerharz CD, Moll R, Storkel S, Ramp U, Hildebrand B, Molsberger G, Koldovsky P, and Gabbert HE (1995). Establishment and characterization of two divergent cell lines derived from a human chromophobe renal cell carcinoma. Am J Pathol 146:953-962.
13. Gerharz CD, Moll R, Störkel S, Ramp U, Thoenes W, and Gabbert HE (1993). Ultrastructural appearance and cytoskeletal architecture of the clear, chromophilic and chromophobe cell variants of human renal cell carcinoma in vivo and in vitro. Am J Pathol 142:851-859.
14. Gerharz CD, Ramp U, Olert J, Moll R, Störkel S, Marx N, and Gabbert HE (1994). Cytomorphological, cytogenetic, and molecular biological characterization of four new human renal carcinoma cell lines of the clear cell type. Virchows Arch B 424:403-409.
15. Gomella LG, Sargent ER, Linehan WM, and Kasid A (1989a). Transforming growth factor-beta inhibits the growth of renal cell carcinoma in vitro. J Urol 141:1240-1244.
16. Gomella LG, Sargent ER, Wade TP, Anglard P, Linehan WM, and Kasid A (1989b). Expression of transforming growth factor alpha in normal human adult kidney and enhanced expression of transforming growth factors alpha and beta1 in renal cell carcinoma. Cancer Res 49:6972-6975.
17. Hahn SA, Schutte M, Shamsul Hoque ATM, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, and Kern SE (1996). DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271:350-353.
18. 1 by human glioblastoma cells. Biochem J 277:165-173.
19. 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immuno-suppression in malignant glioma. J Neurosurg 78:944-951.
20. Kekow J and Wiedemann GJ (1995). Transforming growth factor beta: A cytokine with multiple actions in oncology and potential clinical applications (review). Int J Oncol 7:1427-1432.
21. Kellerer M, von Eye Corleta H, Mühlhöfer A, Capp E, Mosthaf L, Bock S, Petrides PE, and Häring HU (1995). Insulin- and insulin-like growth-factor-I receptor tyrosine-kinase activities in human renal carcinoma. Int J Cancer 62:501-507.
22. 2 production and autocrine growth control in osteosarcoma cells. Int J Cancer 58:440-445.
23. 1 and its latent form binding protein in cultured breast carcinoma cells. Cancer Res 55:1540-1546.
24. Kovacs G and Frisch S (1989). Clonal chromosome abnormalities in tumor cells from patients with sporadic renal cell carcinomas Cancer Res 49:651-659.
25. Lawrence DA (1995). Transforming growth factor-beta: An overview. Kidney Int 47:S19-S23.
26. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, Brattain M, and Willson JKV (1995). Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268:1336-1338.
27. Massague J (1992). Receptors for the TGF-β family. Cell 69:1067-1070.
28. Miettinen PJ, Ebner R, Lopez AR, and Derynck R (1994). TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: Involvement of type I receptors. J Cell Biol 127:2021-2036.
29. Moustakas A, Lin HY, Henis YI, Plamondon J, O'Connor-McCourt MD, and Lodish HF (1993). The transforming growth factor β receptors types I, II, and III form hetero-oligomeric complexes in the presence of ligand. J Biol Chem 268: 22215-22218.
30. Myeroff LL, Parsons R, Kim S-J, Hedrick L, Cho KR, Orth K, Mathis M, Kinzler KW, Lutterbaugh J, Park K, Bang Y-J, Lee HY, Park J-G, Lynch HT, Roberts AB, Vogelstein B, and Markowitz SD (1995). A transforming growth factor beta receptor type II gene muation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res 55:5545-5547.
31. Otani N, Tsukamoto T, Masumori N, Saiki I, Yoneda J, and Kumamoto Y (1994). Influence of growth factors on in vitro invasiveness and type IV collagenolysis of human renal cell carcinoma cells. J Urol 151:223-226.
32. Parsons R, Myeroff LL, Liu B, Willson JKV, Markowitz SD, Kinzler KW, and Vogelstein B (1995). Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res 55:5548-5550.
33. 1 on in vitro angiogenesis. Exp Cell Res 204:356-363.
34. Petrides PE, Bock S, Bovens J, Hofmann R, and Jakse G (1990). Modulation of pro-epidermal growth factor, pro-transforming growth factor alpha and epidermal growth factor receptor gene expression in human renal carcinomas. Cancer Res 50:3934-3939.
35. Pitz S, Moll R, Störkel S, and Thoenes W (1987). Expression of intermediate filament proteins in subtypes of renal cell carcinomas and in renal oncocytomas: Distinction of two classes of renal cell tumors. Lab Invest 56:642-653.
36. Ramp U, Gerharz CD, Doehmer J, Oster O, and Gabbert HE (1992). Increase in proto-oncogene raf expression precedes differentiation induction in different clonal rhabdomyosarcoma subpopulations. Anticancer Res 12:537-546.
37. Reddy KB, Hocevar BA, and Howe PH (1994). Inhibition of G1 phase cyclin dependent kinases by transforming growth factor betal. J Cellular Biochem 56:418-425.
38. 1 in murine keratinocytes. Cancer Res 53:899-904.
39. Roberts AB and Sporn MB (1990). The transforming growth factor-betas. In: Sporn MB and Roberts AB, editors. Peptide growth factors and their receptors: Handbook of experimental pharmacology. Berlin: Springer Verlag, 419-472.
40. Sargent ER, Gomella LG, Belldegrun A, Linehan WM, and Kasid A (1989). Epidermal growth factor gene expression in normal human kidney and renal cell carcinoma. J Urol 142:1364-1368.
41. Serra R and Moses HL (1996). Tumor suppressor genes in the TGF-beta signalling pathway? Nature Med 2:390-391.
42. Sovova V, Sloncova E, Damkova M, Vydra J, and Jakoubkova J (1993). Activity of PDGF (A) gene in the human cell line derived from a renal carcinoma metastasis. Folia Biol 39:40-46.
43. Stampfer MR, Yaswen P, Alhadeff M, and Hosoda J (1993). TGF β induction of extracellular matrix associated proteins in normal and trans-formed human mammary epithelial cells in culture is independent of growth effects. J Cell Physiol 155:210-221.
44. Störkel S, Thoenes W, Jacobi GH, and Lippold R (1989). Prognostic parameters in renal cell carcinoma: A new approach. Eur Urol 16:416-422.
45. Thoenes W, Störkel S, and Rumpelt HJ (1986). Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). Pathol Res Pract 181:125-143.
46. Uhlman DL, Nguyen PL, Manivel JC, Aeppli D, Resnick JM, Fraley EE, Zhang G, and Niehaus GA (1994). Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J Natl Cancer Inst 86:1470-1475.
47. Wade TP, Kasid A, Stein CA, LaRocca RV, Sargent ER, Gomella LG, Myers CE, and Linehan WM (1992). Suramin interference with transforming growth factor-beta inhibition of human renal cell carcinoma in culture. J Surg Res 53:195-198.
48. Walker C, Everitt J, Freed JJ, Knudson AG Jr, and Whiteley LO (1991). Altered expression of transforming growth factor-alpha in hereditary rat renal cell carcinoma. Cancer Res 51:2973-2978.
49. Wrana JL, Attisano L, Wieser R, Ventura F, and Massague J (1994). Mechanism of activation of the TGF-beta receptor. Nature 370:341-347.